However, patients whose treatment involved rapamycin for the inhibition of ribosomal protein S6 kinase beta-1 (S6K1), the downstream target of mTORC complex, experienced some beneficial effects, including slower tumor growth [27]. The gene discussed is RPS6KB1; the disease is neoplasm.